cyrilzakka/clinical-trials huggingface dataset:
Catheter Ablation for Atrial Fibrillation and Heart Failure

To compare heart function, symptoms, exercise capacity and quality of life in patients with Congestive Heart Failure (CHF) and Atrial Fibrillation (AF)before and after catheter ablation.

Hypothesis: Restoration and maintenance of sinus rhythm by catheter ablation, without the use of antiarrhythmic drugs, in AF and CHF improves heart failure status.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years to 80 years
* Clinical diagnosis of CHF based on symptoms (Shortness of breath, fatigue, peripheral edema)
* Systolic left ventricular dysfunction with ejection fraction 40% or less
* NYHA Class I, II or III heart failure
* Paroxysmal AF(2 or more episodes in one month) that terminate within 7 days:or persistent AF (more than 7 days or less than 7 days but terminated with pharmacologic or electrical cardioversion).
* Willing and able to sign informed consent

Exclusion Criteria:

* Previous ablation
* Left atrial size greater than 60mm(parasternal view on transthoracic echocardiogram)
* AF episodes triggered by another uniform arrhythmia(e.g.atrial flutter or atrial tachycardia)
* Active alcohol or drug abuse, which may be causative of AF
* Severe valvular disease requiring surgical repair
* Myocardial infarction within 6 months of enrollment
* Abnormality that prevents catheter introduction
* Coronary surgical revascularization or other cardiac surgery within 6 months of enrollment
* Patients in whom heart transplant expected with 6 months
* AF deemed secondary to a transient or correctable cause (e.g.electrolyte imbalance ,trauma,recent surgery,,infection, toxic ingestion or endocrinopathy
* Pregnancy or women of child bearing potential \& not on reliable method of birth control
* Contraindication to Warfarin therapy or other bleeding diathesis
* Participation in another clinical trial
* Inaccessable to follow-up
* Life expectancy of less than 24 months caused by reasons other than heart disease
* Renal failure requiring dialysis
* Decompensated CHF within 48 Hours of enrollment
* Second or third degree AV block or sinus pause greater than 3 seconds, resting heart rate less 30 bpm without a permanent pacemaker
* A history of drug induced Torsades de Pointes or congenital long QT syndrome
* Currently responding to antiarrhythmic drug therapy
* Uninterrupted AF for more than 12 months prior to randomization unless sinus rhythm maintained for 24 hours or longer.
* Unwilling or unable to sign informed consent
Screening for Chronic Hepatitis C Virus in Hospitalized Patients

Chronic viral hepatitis C is a public health problem and several management recommendations are available. According to the HAS, hepatitis C screening consists of a targeted screening of people at risk of infection by the virus, in particular to drug users, to people from countries with a high prevalence of the virus or who have received care in those countries, people transfused before 1992, or people who have been or have been imprisoned. Our study proposes to evaluate hepatitis C screening in consenting patients hospitalized in Saint Joseph. These previously identified patients with comorbidities will be cared for according to current national practices that reduce HCV morbidity and mortality.

Hepatitis C screening is based on a blood test, in particular the Elisa test, which looks for anti-HCV antibodies. In the case of positive C viral serology, the search for the C virus from a blood test makes it possible to detect the genome (RNA) of the virus, which is thus directly detected by a so-called "PCR" technique. Although screening activity is important in France, it remains insufficient. In December 2016, HAS concluded that risk-based targeted screening has limitations and contributes to the persistence of a hidden epidemic of viral C infection. It is estimated that 75,000 people are unaware of being carriers of the hepatitis C virus. However, there is safe, effective and well-tolerated treatment. With duration of 8 to 12 weeks it allows a healing of HCV in more than 95% of subjects. AFEF recommendations aim to achieve viral elimination C (as early as 2025). This elimination is defined as a 90% decrease in new infections associated with a 65% reduction in HCV mortality. OMS has planned this target for 2030. To achieve this goal, a number of measures are gradually being implemented focusing on universal treatment and universal screening. The hospital may be a place where systematic screening is interesting. In 2017, the prevalence of anti-HCV positive antibodies in the facility, apart from the Hepato-Gastroenterology service, was 1.7%, more than twice the estimated prevalence in our general population. These data give a rationale for the realization of this study.

Eligibility Criteria:
Inclusion Criteria:

* all in-patient patients and consenting to participate at the study.

Exclusion Criteria:

* Refusal to participate in the study
* Contraindication to a blood sample (Impossibility of a peripheral venous approach and any clinical condition that may indicate a venous sample)
* Minor patient
* Patient unable to express consent
Changing Dietary Patterns: an Individually Tailored Nutrition Intervention (OKE-study)

The main objective of this study is to investigate the effect of a personalized nutrition intervention on the dietary pattern of apparently healthy adults with one or more children aged 4 to 12 years.

Giving personalized nutrition advice is perceived to be more effective in changing dietary patterns than giving general information about healthy eating.

Eligibility Criteria:
Inclusion Criteria:

* At least aged 18 years
* Having one child aged 4 to 12 years
* Written informed concent has been obtained

Exclusion Criteria:

* Not meeting the inclusion criteria
* Unable or unwilling to comply with the study procedures
* Enrolled in another study during the same study period
* Not being able to communicate (read, speak and write) in the Dutch language
* Having a partner who has been enrolled in the study
* Being pregnant or lactating during the study period or planning to become pregnant during the study period
* Having a BMI lower than 18.5 or higher that 35 kg/m2
* Using medication to lower cholesterol or being under control by a doctor for having too high cholesterol levels
* Using medication to lower blood pressure or being under control by a doctor for having a high blood pressure.
* Having diabetes type I or type II
* Following a diet (medical or self-initiated) or planning to follow a diet during the study period
* Undergoing a medical treatment that interferes with the intervention.
* Having gained or lost more than 5 kg of body weight during the last 6 months.
Hydroxychloroquine in COVID-19 Patients

Many reports argued about the possible beneficial effects of Hydroxychloroquine in treating COVID-19 patients and this study was designed to investigate this claim


Eligibility Criteria:
Inclusion Criteria:

Confirmed cases of SARS-CoV-2 by PCR

Exclusion Criteria:

less than 18 years old known hypersensitivity to the drug
Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy

This Compassionate Use Program (CUP) is setup to provide study patients with continuous access to Brivaracetam (BRV) for the time period between closures of the long-term follow up studies N01125, N01199, N01372, N01379, and N01315 and when BRV is commercially available.


Eligibility Criteria:
Inclusion Criteria:

* Patients with epilepsy who are participating in Brivaracetam (BRV) studies N01125, N01199, N01372, N01379 or N01315
* Patients for whom the treating physician believes there is a continued benefit from the long-term administration of BRV and other anti-epileptic therapies might not be suitable for the patient
* Female patients without childbearing potential are eligible
* Female patients with childbearing potential are eligible if they use a medically accepted contraceptive method for the duration of the Compassionate Use Program (CUP) participation. The patient must understand the consequences and potential risks of inadequately protected sexual activity, be educated about and understand the proper use of contraceptive methods, and inform the treating physician of any potential change in status
* Patient is considered reliable and capable of adhering to medication intake.
* Patient is informed of the details of this CUP, is given ample time and opportunity to ask questions and consider his/her participation in this CUP, and the patient or the legally authorized representative (LAR) has provided verbal consent to participate, and, if required under local regulations, has given written informed consent

Exclusion Criteria:

* Severe medical, neurological and psychiatric disorders, including current suicidal ideation or behavior, or laboratory values which may have an impact on the safety of the patient, as determined by the treating physician
* Poor compliance with medication intake in the previous BRV study
* Participation in any clinical study of another investigation drug or device during the CUP
* Pregnant or lactating woman
Phase 1 to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females

- Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects. Secondary objective_To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) characteristics after single oral administration of the IP, J2H-1702 in healthy female subjects.

- Study Methodology: 6 Subjects will be randomized to the study group (J2H-1702 group) and 2 subjects will be to the placebo group. AE, VS, ECG, Lab tests will be evaluated to check the safety, tolerability and PK/PD.

Eligibility Criteria:
Inclusion Criteria:

1. Healthy females aged ≥ 19 and ≤ 45 years
2. Subjects with a body mass index (BMI) ≥ 18.0 to ≤ 27.0 kg/m2
3. Subjects confirmed to be clinically healthy based on the medical history, physical examination, vital signs, electrocardiogram (ECG), and appropriate clinical laboratory tests
4. Agree to use dual contraceptive methods and not to donate eggs
5. Voluntarily agree to participate in the study

Exclusion Criteria:

1. A subject who had or has the disease corresponding to clinically significant liver, etc.
2. A subject with a history of gastrointestinal diseases or surgery
3. A subject who has a history of clinically significant hypersensitivity to drugs containing 11β-HSD1 inhibitor
4. A subject who has genetic problems such as galactose intolerance, Lap galactose intolerance, Lap lactase deficiencies, or glucose ∙galactose malabsorptivity, etc.
5. One who has drug abuse and one who is positive response in urine drug screening tests
6. A subject with abnormal vital signs at the screening visit
7. A subject who has participated in another clinical trial or bioequivalence test
8. A subject who donated whole blood or the ingredient, or received blood transfusion
9. A subject who took drug metabolizing enzyme-inducing and inhibitory drugs
10. A subject who consumes grapefruit/caffeine-containing food
11. A subject who took any prescription drug or herbal medicine or took any Over The Counter Drug (OTC)
12. High caffeine intaker, high alcohol intaker or excessive smoker
13. A subject who cannot eat meals provided by the Clinical Trial institution.
14. A subject who participated in this trial and were administered the investigational product.
15. A subject who is positive for serum test
16. A pregnant or breast-feeding subject
17. A subject who the investigator deems inappropriate for this clinical trial
Trends in Volume-Outcome Relationship in Surgery

The explanatory mechanism of the relationship between the volume of surgical procedures performed by individual hospitals and the occurrence of serious adverse events is not clear. Based on the " practice makes perfect " dogma, we will explore whether a learning effect can explain the volume-outcome relationship for complex surgical procedures using a nationwide dataset. Especially, we assume that increasing volume of procedures over time may be associated with improved outcomes.


Eligibility Criteria:
Inclusion Criteria:

All adults hospitalized to have one of the following major surgery: resection of oeso-gastric, intestinal and pancreatic cancer, treatment of intra-abdominal aortic aneurysm, coronary artery bypass graft, endarterectomy, hip fracture prosthesis

Exclusion Criteria:

* Hospitalization \<24 hours
* Absence of surgical procedure
* Ambulatory care
* Palliative care
* Organ transplantation
Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL)

The objective of this study is to translate the "AKQoL"-questionnaire which measures the quality of life of patients with actinic keratosis into German and to validate it for the Swiss population.

By using the technique of cognitive interviewing the investigators are focussing on the patients' understanding of the questions. The first session of cognitive interviews will show, where there is need for improvement in terms of misinterpreted phrases or vaguely worded questions. The goal is to rephrase the questions according to the feedback of the patients. The revised version will then be presented to a new population.

Actinic keratosis is a UV-induced skin disease, which presents as a reddish, squamous and sometimes itchy lesion. Actinic keratosis seems to have a negative impact on patients' quality of life. Esmann et al. elaborated on patients with actinic keratosis from Zealand, Denmark a questionnaire which measures the quality of life.

The objective of this study is to translate this questionnaire into German and to validate it for the Swiss population. This questionnaire might become part of a planned national register for data collection of patients with AK.

The investigators will assess the content validity of the questionnaire by using the technique of cognitive interviewing. The investigators are going to talk 34 patients with AK from the department of Dermatology, University Hospital Zurich through the translated version. Thereby, the investigators are focusing on the patients' understanding of the questions.

The first session of cognitive interviews will show, where there is need for improvement in terms of misinterpreted phrases or vaguely worded questions. The goal is to rephrase the questions in the sense that they become more clear and are understood by different interviewee in the same way. The revised version will then be presented to a new population. The performance of cognitive interview sessions and revisions will continue until the survey will be approved by at least 80% of the respondents.

Eligibility Criteria:
Inclusion Criteria:

* Patients with actinic keratosis of the department of Dermatology, University Hospital Zurich
* Male and Female subjects \> 18 years of age
* Good understanding of written and spoken German
* Sufficient physical and mental capacity to comprehend the questions
* Written informed consent by the participant

Exclusion Criteria:

* Lack of informed consent
The Right Ventricular Responses to Mild Hypercarbia After Mitral Valve Repair Surgery

The aims of the study is to investigate the right ventricular responses to mild hypercarbia after mitral valve prolapse repair surgery by the measurements obtained on pulmonary arterial catheter and transesophageal echocardiography.

The aims of the study is to investigate the right ventricular responses to mild hypercarbia after mitral valve prolapse repair surgery by the measurements obtained on pulmonary arterial catheter and transesophageal echocardiography. Investigators hypothesize that induced mild hypercarbia (PaCO2 7.5 kPa) cause elevated mean pulmonary arterial pressure and pulmonary vascular resistance, and this reflect to the right ventricle, both volume and function. And this right ventricle effect could be noticed by echocardiography.

Eligibility Criteria:
Inclusion Criteria:

* scheduled mitral valve prolapse repair surgery
* able to give informed consent

Exclusion Criteria:

* preoperative right ventricular dysfunction or pulmonary hypertension
* significant tricuspid regurgitation
* congenital heart defect
* ventricular dyssynchrony or wide QRS-complex on ECG (\> 130 ms)
* prior myocardial infarction (within tree months) or pericardial constriction
* preoperative left ventricular (LV) dysfunction, i.e. LV ejection fraction under 40 %
* if the scheduled repair by plastic procedure has been converted to mitral valve replacement
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study

The goal of this research project is to establish that in short-term use, tolvaptan is a safe and potentially effective new therapy for cystinuria, by conducting a short-term pilot study of the safety and tolerability of this drug, and assess impact on urinary stone risk parameters, among adolescent and young adult patients with clinical cystinuria.


Eligibility Criteria:
Inclusion Criteria:

* Males and females age 12 - 29 years
* Weight ≥ 25kg (55 lbs)
* Confirmed cystinuria diagnosis
* Specific blood test levels (done within the past 6 months)

Exclusion Criteria:

* Concurrent non-renal disease that might increase risk of complications due to aquaresis
* Liver or biliary disease (chronic or acute)
* Malabsorption syndrome or other gastrointestinal condition that may interfere with response to therapy
* Non-cutaneous malignancy within last 5 years
* History of adverse reaction or allergy to Tolvaptan or other arginine vasopressin V2-receptor antagonists
Computed Tomography Evaluation of Urinary Stones Densities Compared to in Vitro Analysis of Its Chemical Composition

The ability to predict stone composition, which influences patient treatment, depends on the accurate measurement of CT attenuation of stones. We will study the effects of stone composition, stone size, and scan collimation width on the measurement of attenuation in vitro.

Recently, the use of noncontrast spiral computerized tomography (NCCT) has gained widespread acceptance in the evaluation of urinary stone patients. It has long been used clinically to evaluate the causes of radiolucent filling defects using Hounsfield units (HU) to distinguish calculi from tumor or blood clots, and to identify nonurologic causes of flank pain (Smith R etal ). Urinary stones have a significantly higher CT attenuation than the surrounding soft tissues and are virtually always visible on NCCT. Knowing the composition of a urinary calculus is frequently a key factor in determining its most appropriate management. Should the urine be alkalinized? Will the stone be amenable to extracorporeal shock wave lithotripsy (ESWL), or should ureteroscopy or percutaneous lithotripsy be attempted? Different techniques have been used to assist in determining the correct chemical composition of calculi. Urine pH, urinary crystals, prior stone history and the presence of urea-splitting organisms (Ramakumar S,etal). Several in vitro studies have suggested that NCCT can demonstrate measured differences in radiodensity among different urinary stones (Mitchenson HD etal,).With these clinical problems in mind, we sought to determine whether the composition of urinary calculi could be predicted by their CT characteristics in an attempt to find out the best technique for distinguishing the various stones compositions, provided that it is clinically practical and would not require repeated imaging of the patients.

Eligibility Criteria:
Inclusion Criteria:

* Any Age will be included .
* Patient with suspected or known urinary stone disease.
* Eligible for doing NCCT.
* Giving written consent to participate

Exclusion Criteria:

* Patient with classical NCCT contraindication like morbid obesity and pregnancy .
* Patients with urinary stones will be treated by ESWL
* Refusal participation .
Effectiveness of Integrated Care Network

This project aims to examine the effectiveness of the community-based integrated care service model , based on a multi-domain intervention program, among community-dwelling older adults. Moreover, the investigators use the value-based healthcare standard set as well as comprehensive geriatric assessment as outcome measures and to use the randomized controlled trial design to validate the clinical effectiveness.

Population aging and the progress of medical technology are two main causes for the increase of healthcare expenditure. Effective management of medical expenditure and maintenance of health care quality have become the most important task for the public health and clinical care services. Both United Kingdom and the World Health Organization proposed introducing interdisciplinary team care to improve health of older people and to maximize their independence. Prof Michael Porter has addressed the current difficulty of healthcare system, and proposed that healthcare system should pursuit long-term outcome to promote the value of health care. This project aims to echo the international trends, using Taiwan healthcare system as the basis to establish the community-based integrated care service model, and to use the randomized controlled trial design to validate the clinical effectiveness.

Eligibility Criteria:
Inclusion Criteria:

* age ≧ 65 years
* three or more chronic conditions, defined by National Health Insurance list of chronic conditions
* covered by National Health Insurance

Exclusion Criteria:

* could not understanding protocol or communication with research nurses
* malignant diseases under active treatments
* life expectancy less than twelve months
* admitted in the long term facility
Water Drinking Test in Patients With Occludable Angle

The water drinking test (WDT), is a predictive test that has been used to detect primary open angle glaucoma and recently has been demonstrated as a predictor of the diurnal tension curve. Clinically accurate provocative tests for asymptomatic eyes with shallow anterior chambers and narrow angles are highly desirable to detect patients prone to angle closure glaucoma. The aim of this pilot study is to evaluate the possible role of water drinking test in patients with narrow angles who are scheduled for prophylactic laser iridotomy.

This prospective case series will investigate the effects of the WDT on subjects with narrow anterior chamber angles on the day of their scheduled laser iridotomy. The angle configuration and IOP will be monitored following the WDT. Twenty patients with occludable angles will be enrolled in this study. After measuring the baseline IOP, weight and height, the patients will be asked to drink 10ml/kg water over 15 minutes (equal to approximately 0.33 ounces of water for every 2.2 pounds of weight or 2 ½ cups for a 150 lb. individual) and their IOP will be checked every 15 minutes up to one hour after drinking the water. This will be repeated after performing a laser iridotomy. The data obtained, mainly IOP and gonioscopic findings, will be analyzed using statistical tests and compared to historical controls of the WDT without narrow angles, and laser iridotomy subjects without the WDT.

Eligibility Criteria:
Inclusion Criteria:

* narrow angle judged to be at risk of attack by the treating physician, with one or more quadrants not open to the sclera spur on gonioscopy
* age between 21 and 90 years
* ability to give informed consent.

Exclusion Criteria:

* baseline IOP higher than 21 mm Hg with or without medication
* other causes of glaucoma, such as pseudoexfoliative and pigmentary glaucomas
* previous treatment with argon laser or selective laser trabeculoplasty
* previous refractive sugary; (5) pregnant women; (6) congestive heart failure
* renal failure or urinary retention issues; (8) corneal abnormalities preventing reliable IOP measurement
* non-glaucomatous optic neuropathy
* prior refractive surgery or other issues preventing accurate Goldmann applanation tonometry
* prior intraocular surgery